Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Estrogens; Estrogens, Conjugated (USP); Polyestradiol phosphate; Progesterone

Criteria

Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to ovarian failure

• Outpatients

• age >=12 years to 17.99 years old

Exclusion Criteria:

• spontaneous menses

• significant concurrent medical problem including:

• Liver function tests (LFTs) 3 times normal

• clotting disorder

• ongoing cancer treatment